BR112013013646A2 - derivados de benzil azetina como moduladores de esfingosina 1-fosfato (s1p) - Google Patents
derivados de benzil azetina como moduladores de esfingosina 1-fosfato (s1p)Info
- Publication number
- BR112013013646A2 BR112013013646A2 BR112013013646A BR112013013646A BR112013013646A2 BR 112013013646 A2 BR112013013646 A2 BR 112013013646A2 BR 112013013646 A BR112013013646 A BR 112013013646A BR 112013013646 A BR112013013646 A BR 112013013646A BR 112013013646 A2 BR112013013646 A2 BR 112013013646A2
- Authority
- BR
- Brazil
- Prior art keywords
- azetine
- sphingosine
- modulators
- benzyl
- phosphate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Transplantation (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41929310P | 2010-12-03 | 2010-12-03 | |
PCT/US2011/060404 WO2012074722A1 (en) | 2010-12-03 | 2011-11-11 | Novel benzyl azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013013646A2 true BR112013013646A2 (pt) | 2016-09-06 |
Family
ID=45048252
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013013639A BR112013013639A2 (pt) | 2010-12-03 | 2011-11-09 | derivados de azetidina como moduladores do receptor de esfingosina-1-fosfato (s1p) |
BR112013013646A BR112013013646A2 (pt) | 2010-12-03 | 2011-11-11 | derivados de benzil azetina como moduladores de esfingosina 1-fosfato (s1p) |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013013639A BR112013013639A2 (pt) | 2010-12-03 | 2011-11-09 | derivados de azetidina como moduladores do receptor de esfingosina-1-fosfato (s1p) |
Country Status (10)
Country | Link |
---|---|
US (5) | US8501726B2 (pt) |
EP (2) | EP2646023B1 (pt) |
JP (2) | JP2013544831A (pt) |
KR (2) | KR20130133233A (pt) |
CN (2) | CN103338764A (pt) |
AU (2) | AU2011337068A1 (pt) |
BR (2) | BR112013013639A2 (pt) |
CA (2) | CA2819666A1 (pt) |
RU (2) | RU2013130019A (pt) |
WO (2) | WO2012074703A1 (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8735433B1 (en) | 2012-11-14 | 2014-05-27 | Allergan, Inc. | Aryl oxadiazole derivatives as sphingosine 1-phosphate (S1P) receptor modulators |
US8846729B2 (en) | 2012-11-14 | 2014-09-30 | Allergan, Inc. | 2-thio-1,3,4-oxadiazoles azetidine derivatives as sphingosine-1 phosphate receptors modulators |
US20150057261A1 (en) * | 2013-08-21 | 2015-02-26 | Allergan, Inc. | Azetidine derivatives as sphingosine-1 phosphate receptors modulators |
WO2015073140A1 (en) * | 2013-11-14 | 2015-05-21 | Allergan, Inc. | 1,3,4-alkenyl oxadiazole amino acid derivatives as sphingosine-1-phosphate receptors' modulators |
WO2015108577A1 (en) * | 2014-01-15 | 2015-07-23 | Allergan, Inc. | Diphenyl urea derivatives as formyl peptide receptor modulators |
JP6770511B2 (ja) | 2014-09-29 | 2020-10-14 | ザ スクリプス リサーチ インスティテュート | 心肺障害の処置のためのスフィンゴシン−1−リン酸受容体モジュレーター |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1053825A (pt) * | 1963-03-22 | |||
WO2003105771A2 (en) * | 2002-06-17 | 2003-12-24 | Merck & Co., Inc. | 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists |
US20060252741A1 (en) | 2003-05-15 | 2006-11-09 | Colandrea Vincent J | 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists |
NZ577111A (en) * | 2006-12-15 | 2012-05-25 | Abbott Lab | Novel oxadiazole compounds |
WO2008091967A1 (en) * | 2007-01-26 | 2008-07-31 | Smithkline Beecham Corporation | Chemical compounds |
ES2405054T3 (es) * | 2009-01-23 | 2013-05-30 | Bristol-Myers Squibb Company | Derivados de pirazol-1,2,4-oxadiazol como agonistas de esfingosina-1-fosfato |
CN102361867A (zh) * | 2009-01-23 | 2012-02-22 | 百时美施贵宝公司 | 在治疗自身免疫疾病和炎性疾病中作为s1p激动剂的取代的噁二唑衍生物 |
-
2011
- 2011-11-09 CA CA2819666A patent/CA2819666A1/en not_active Abandoned
- 2011-11-09 EP EP11788690.3A patent/EP2646023B1/en not_active Not-in-force
- 2011-11-09 RU RU2013130019/04A patent/RU2013130019A/ru not_active Application Discontinuation
- 2011-11-09 CN CN2011800658078A patent/CN103338764A/zh active Pending
- 2011-11-09 JP JP2013542011A patent/JP2013544831A/ja active Pending
- 2011-11-09 AU AU2011337068A patent/AU2011337068A1/en not_active Abandoned
- 2011-11-09 WO PCT/US2011/060006 patent/WO2012074703A1/en active Application Filing
- 2011-11-09 BR BR112013013639A patent/BR112013013639A2/pt not_active IP Right Cessation
- 2011-11-09 KR KR1020137017282A patent/KR20130133233A/ko not_active Application Discontinuation
- 2011-11-10 US US13/293,687 patent/US8501726B2/en not_active Expired - Fee Related
- 2011-11-11 EP EP11788715.8A patent/EP2646024B1/en not_active Not-in-force
- 2011-11-11 US US13/294,460 patent/US8729062B2/en active Active
- 2011-11-11 BR BR112013013646A patent/BR112013013646A2/pt not_active IP Right Cessation
- 2011-11-11 KR KR1020137017290A patent/KR20130137658A/ko not_active Application Discontinuation
- 2011-11-11 JP JP2013542017A patent/JP2014502273A/ja active Pending
- 2011-11-11 CN CN2011800664971A patent/CN103370065A/zh active Pending
- 2011-11-11 CA CA2819594A patent/CA2819594A1/en not_active Abandoned
- 2011-11-11 WO PCT/US2011/060404 patent/WO2012074722A1/en active Application Filing
- 2011-11-11 RU RU2013130022/04A patent/RU2013130022A/ru not_active Application Discontinuation
- 2011-11-11 AU AU2011337087A patent/AU2011337087A1/en not_active Abandoned
-
2013
- 2013-06-28 US US13/930,281 patent/US8906899B2/en not_active Expired - Fee Related
-
2014
- 2014-01-06 US US14/148,468 patent/US20140128369A1/en not_active Abandoned
- 2014-04-02 US US14/243,599 patent/US20140213573A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2819594A1 (en) | 2012-06-07 |
CN103338764A (zh) | 2013-10-02 |
US20140128369A1 (en) | 2014-05-08 |
CA2819666A1 (en) | 2012-06-07 |
EP2646024B1 (en) | 2014-10-22 |
US8501726B2 (en) | 2013-08-06 |
US20130303513A1 (en) | 2013-11-14 |
US20140213573A1 (en) | 2014-07-31 |
KR20130133233A (ko) | 2013-12-06 |
JP2014502273A (ja) | 2014-01-30 |
EP2646023A1 (en) | 2013-10-09 |
RU2013130019A (ru) | 2015-01-10 |
EP2646024A1 (en) | 2013-10-09 |
KR20130137658A (ko) | 2013-12-17 |
CN103370065A (zh) | 2013-10-23 |
RU2013130022A (ru) | 2015-01-10 |
WO2012074703A1 (en) | 2012-06-07 |
US8906899B2 (en) | 2014-12-09 |
US20120142663A1 (en) | 2012-06-07 |
US8729062B2 (en) | 2014-05-20 |
BR112013013639A2 (pt) | 2016-09-06 |
US20120142664A1 (en) | 2012-06-07 |
JP2013544831A (ja) | 2013-12-19 |
AU2011337068A1 (en) | 2013-07-11 |
EP2646023B1 (en) | 2015-01-07 |
AU2011337087A1 (en) | 2013-07-11 |
WO2012074722A1 (en) | 2012-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LTPA2020529I1 (lt) | Sfingozino fosfato receptorių nauji moduliatoriai | |
IL254839A0 (en) | s1p modulatory factors | |
BR112014015087A2 (pt) | derivados de benzil sulfonamida como moduladores de rorc | |
EP2751771A4 (en) | HEALTH MANAGEMENT SYSTEM | |
BR112012030948A2 (pt) | monitor de progresso de administração de atividade | |
HK1184153A1 (zh) | 作為 調節劑的螺-哌啶衍生物 | |
BR112013015234A2 (pt) | derivados fosforosos como moduladores de receptor de quimiocina | |
EP2344446A4 (en) | S1P RECEPTOR MODULATORS | |
IL228945A0 (en) | Modified bicyclylmethylamine derivatives as sphingosine-1-phosphate receptor modulators | |
BRDI7104779S (pt) | Configuração aplicada em instrumento médico | |
EP2706999A4 (en) | SELECTIVE HETEROCYCLIC SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATORS | |
BR112013013037A2 (pt) | derivados de indol como moduladores dos receptores de s1p | |
HK1212792A1 (zh) | 分佈式應用生命週期管理的解決方案 | |
BR112013013633A2 (pt) | derivados de alquina e alceno como moduladores do receptor de esfingosina 1-fosfato-1 | |
HK1179956A1 (zh) | 作為 調節劑的稠合雜環衍生物 | |
BR112013013646A2 (pt) | derivados de benzil azetina como moduladores de esfingosina 1-fosfato (s1p) | |
EP2900058A4 (en) | LIGAMENT CARRIER FOR HOOF | |
BR112013013643A2 (pt) | derivados de oxadiazol como moduladores de receptor de esfingosina-1-fosfato (s1p) | |
EP2691930A4 (en) | LICENSE UPDATE MANAGEMENT | |
DK2668397T3 (da) | Stiv til elastisk elektrodeforbindelse | |
BR112013013640A2 (pt) | derivados de oxima como moduladores de receptores de esfingosina-1-fosfato (s1p) | |
GB201107790D0 (en) | Medical simulation system | |
EP2796459A4 (en) | NEW S1P RECEIVER MODULATOR | |
BR112013032873A2 (pt) | arranjo de distribuição rotativo | |
BR112014005889A2 (pt) | métodos de modulação de pegajosidade |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |